Literature DB >> 3199071

Cellularly defined minor histocompatibility antigens are differentially expressed on human hematopoietic progenitor cells.

P J Voogt1, E Goulmy, W F Veenhof, M Hamilton, W E Fibbe, J J Van Rood, J H Falkenburg.   

Abstract

Previously, five CTL lines directed against minor histocompatibility (mH) antigens designated HA-1-5 have been established from peripheral blood of patients after allogeneic bone marrow transplantation (BMT), and have been characterized using population and family studies. All cell lines showed specific HLA class I-restricted lysis of PHA-stimulated peripheral blood target cells from donors positive for the particular mH antigens. After 4 h of incubation of the mH antigen HA-3-specific CTL line with bone marrow cells from HA-3+ donors, complete class I-restricted inhibition of colony growth of the hematopoietic progenitor cells was observed even at low E/T ratios, indicating that the HA-3 antigen is strongly expressed on hematopoietic stem cells. Therefore, this antigen may be a target structure in the immune-mediated rejection of the hematopoietic graft in case of incompatibility for this determinant between donor and recipient in allogeneic BMT. In contrast, incubation of bone marrow cells with the antigen-specific anti-HA-1, -2, -4, and -5 CTL lines did not result in growth inhibition of the hematopoietic progenitor cells tested. After a prolonged incubation time and using a very high E/T ratio, progenitor cells from HA-2+ or HA-5+ donors were killed to some extent by the anti-mH-specific CTL lines, although the growth inhibition observed was minor and variable. Our results show that mH antigens are differentially expressed on human hematopoietic progenitor cells. Therefore, only some of these antigens may be targets in immune-mediated rejection of the bone marrow graft.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3199071      PMCID: PMC2189144          DOI: 10.1084/jem.168.6.2337

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  28 in total

Review 1.  Bone-marrow transplantation (first of two parts).

Authors:  E Thomas; R Storb; R A Clift; A Fefer; F L Johnson; P E Neiman; K G Lerner; H Glucksberg; C D Buckner
Journal:  N Engl J Med       Date:  1975-04-17       Impact factor: 91.245

2.  Differential effects of human granulocytes and lymphocytes on human fibroblasts in vitro.

Authors:  G Lundgren; C F Zukoski; G Möller
Journal:  Clin Exp Immunol       Date:  1968-10       Impact factor: 4.330

3.  Colony formation by normal and leukemic human marrow cells in culture: effect of conditioned medium from human leukocytes.

Authors:  N N Iscove; J S Senn; J E Till; E A McCulloch
Journal:  Blood       Date:  1971-01       Impact factor: 22.113

4.  Cell-mediated lysis of human hematopoietic progenitor cells.

Authors:  P J Voogt; W E Fibbe; W F Veenhof; A Brand; E Goulmy; J J van Rood; J H Falkenburg
Journal:  Leukemia       Date:  1987-05       Impact factor: 11.528

Review 5.  Human marrow transplantation: an immunological perspective.

Authors:  P J Martin; J A Hansen; R Storb; E D Thomas
Journal:  Adv Immunol       Date:  1987       Impact factor: 3.543

6.  Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors.

Authors:  H Glucksberg; R Storb; A Fefer; C D Buckner; P E Neiman; R A Clift; K G Lerner; E D Thomas
Journal:  Transplantation       Date:  1974-10       Impact factor: 4.939

7.  Minor histocompatibility antigen H-Y is expressed on human hematopoietic progenitor cells.

Authors:  P J Voogt; E Goulmy; W E Fibbe; W F Veenhof; A Brand; J H Falkenburg
Journal:  J Clin Invest       Date:  1988-09       Impact factor: 14.808

8.  Treatment of donor bone marrow with monoclonal anti-T-cell antibody and complement for the prevention of graft-versus-host disease. A prospective, randomized, double-blind trial.

Authors:  R T Mitsuyasu; R E Champlin; R P Gale; W G Ho; C Lenarsky; D Winston; M Selch; R Elashoff; J V Giorgi; J Wells
Journal:  Ann Intern Med       Date:  1986-07       Impact factor: 25.391

9.  Bone marrow transplantation for patients with chronic myeloid leukemia.

Authors:  J M Goldman; J F Apperley; L Jones; R Marcus; A W Goolden; R Batchelor; G Hale; H Waldmann; C D Reid; J Hows
Journal:  N Engl J Med       Date:  1986-01-23       Impact factor: 91.245

10.  Prevention of graft failure by an anti-HLFA-1 monoclonal antibody in HLA-mismatched bone-marrow transplantation.

Authors:  A Fischer; C Griscelli; S Blanche; F Le Deist; F Veber; M Lopez; M Delaage; D Olive; C Mawas; G Janossy
Journal:  Lancet       Date:  1986-11-08       Impact factor: 79.321

View more
  10 in total

1.  Preclinical Strategies to Identify Off-Target Toxicity of High-Affinity TCRs.

Authors:  Helena M Bijen; Dirk M van der Steen; Renate S Hagedoorn; Anne K Wouters; Linda Wooldridge; J H Frederik Falkenburg; Mirjam H M Heemskerk
Journal:  Mol Ther       Date:  2018-02-23       Impact factor: 11.454

2.  Presentation of human minor histocompatibility antigens by HLA-B35 and HLA-B38 molecules.

Authors:  J Yamamoto; A Kariyone; N Akiyama; K Kano; M Takiguchi
Journal:  Proc Natl Acad Sci U S A       Date:  1990-04       Impact factor: 11.205

Review 3.  Exploiting T cells specific for human minor histocompatibility antigens for therapy of leukemia.

Authors:  Marie Bleakley; Stanley R Riddell
Journal:  Immunol Cell Biol       Date:  2011-02-08       Impact factor: 5.126

Review 4.  Graft-versus-host disease after donor leukocyte infusions: presentation and management.

Authors:  Noelle V Frey; David L Porter
Journal:  Best Pract Res Clin Haematol       Date:  2008-06       Impact factor: 3.020

5.  Cellular therapy following allogeneic stem-cell transplantation.

Authors:  Alison Rager; David L Porter
Journal:  Ther Adv Hematol       Date:  2011-12

6.  Recognition of clonogenic leukemic cells, remission bone marrow and HLA-identical donor bone marrow by CD8+ or CD4+ minor histocompatibility antigen-specific cytotoxic T lymphocytes.

Authors:  L M Faber; J van der Hoeven; E Goulmy; A L Hooftman-den Otter; S A van Luxemburg-Heijs; R Willemze; J H Falkenburg
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

7.  Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes.

Authors:  J H Falkenburg; H M Goselink; D van der Harst; S A van Luxemburg-Heijs; Y M Kooy-Winkelaar; L M Faber; J de Kroon; A Brand; W E Fibbe; R Willemze
Journal:  J Exp Med       Date:  1991-07-01       Impact factor: 14.307

8.  Successful Transplantation of Retinal Pigment Epithelial Cells from MHC Homozygote iPSCs in MHC-Matched Models.

Authors:  Sunao Sugita; Yuko Iwasaki; Kenichi Makabe; Hiroyuki Kamao; Michiko Mandai; Takashi Shiina; Kazumasa Ogasawara; Yasuhiko Hirami; Yasuo Kurimoto; Masayo Takahashi
Journal:  Stem Cell Reports       Date:  2016-09-15       Impact factor: 7.765

9.  Minor histocompatibility antigen-specific cytotoxic T cell lines, capable of lysing human hematopoietic progenitor cells, can be generated in vitro by stimulation with HLA-identical bone marrow cells.

Authors:  W A Marijt; W F Veenhof; A Brand; E Goulmy; W E Fibbe; R Willemze; J J van Rood; J H Falkenburg
Journal:  J Exp Med       Date:  1991-01-01       Impact factor: 14.307

10.  Generation of leukemia-reactive cytotoxic T lymphocyte clones from the HLA-identical bone marrow donor of a patient with leukemia.

Authors:  L M Faber; S A van Luxemburg-Heijs; R Willemze; J H Falkenburg
Journal:  J Exp Med       Date:  1992-11-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.